Adam R. Metwalli, MD, is a Professor in the Howard University College of Medicine and Chief of Urology in the Department of Surgery at Howard University Hospital. Dr. Metwalli is a urologic oncologist trained in robotic surgery and specializing in cancers of the kidney, prostate, bladder, penis and testis.
He joined the Division of Urology at Howard University Hospital in the Spring of 2018 after nearly 7 years as the primary kidney cancer surgeon at the Urologic Oncology Branch (UOB) of the National Cancer Institute in the National Institutes of Health (NIH). Prior to joining the NIH, Dr. Metwalli spent 3 years in private practice as the only fellowship trained urologic oncologist in a large urology group in Baltimore Maryland. During his time with the Urologic Oncology Branch, Dr. Metwalli has expanded the use of robotic surgery in the treatment for multifocal kidney cancer as well as for repeat and salvage renal surgery. As a result, Dr. Metwalli developed a national and international reputation and has been asked to speak on the surgical management of kidney cancer across the country and around the world.
Dr. Metwalli has published over 50 research manuscripts in peer-reviewed journals and has contributed to dozens more as a participant in the Cancer Genome Atlas Research Network. Dr. Metwalli is actively involved in clinical trials research; he was the principal Investigator for a Phase II clinical trial evaluating a novel small molecule radiotracer in patients with clear cell kidney cancer and has been an associate investigator on several other trials.
Prior to joining the UOB, Dr. Metwalli earned the Ruth L. Kirschstein National Research Service Award Research Training Grant from 2005 to 2006 and was awarded the AUA/Praecis Pharmaceuticals Gerald P. Murphy Scholar Award and the Pfizer Scholar in Urology. Dr. Metwalli earned a medical degree from Wake Forest University School of Medicine prior to completing a surgical internship at the University of Louisville Hospital and a urology residency at the Oklahoma University Health Sciences Center. He then completed fellowships in urologic oncology at the University of Texas MD Anderson Cancer Center and at the Urologic Oncology Branch of the National Cancer Institute. Dr. Metwalli is an active member of the Society of Urologic Oncology, the American Urological Association and a board member for the Genitourinary Malignancies DC Regional Oncology Project (GUMDROP) and has previously served as member of the Medical Advisory Board for the National Kidney Foundation--Maryland.